← Eichor
Study identifier: NCT04716803 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis

Condition: Osteo Arthritis Knee  ·  Sponsor: University of California, San Diego

PhaseNA
Planned participants10
Who can joinAll sexes, 45 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this study is to investigate the safety and effectiveness of bone marrow aspirate concentrate (BMAC) in patients with moderate to severe osteoarthritis of the knee. BMAC provides a rich source of mesenchymal stem cells (MSCs) and is a stem cell-based therapy that has been reported to preserve or improve the structure of joints. The Angel System is the device used in this study to concentrate bone marrow from the patient and is intended to separate a mixture of blood and bone marrow and collect plasma rich platelets preoperative to a surgical procedure. The goal of this study is to identify whether BMAC can be an effective and safe treatment for patients with osteoarthritis of the knee.

This description comes directly from the study's public registry record.

Talk to the study team

Kenneth Kalunian, MD  ·  858-246-2381  ·  kkalunian@health.ucsd.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California San Diego Koman Outpatient PavilionLa Jolla, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04716803